Cholagogues and Choleretics: Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic).Dictionaries, MedicalDictionaries as Topic: Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.Dictionaries, ChemicalTerminology as Topic: The terms, expressions, designations, or symbols used in a particular science, discipline, or specialized subject area.Bilirubin: A bile pigment that is a degradation product of HEME.Enterocolitis, Necrotizing: ENTEROCOLITIS with extensive ulceration (ULCER) and NECROSIS. It is observed primarily in LOW BIRTH WEIGHT INFANT.Cholestasis: Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).Ursodeoxycholic Acid: An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.Parenteral Nutrition: The administering of nutrients for assimilation and utilization by a patient who cannot maintain adequate nutrition by enteral feeding alone. Nutrients are administered by a route other than the alimentary canal (e.g., intravenously, subcutaneously).Parenteral Nutrition, Total: The delivery of nutrients for assimilation and utilization by a patient whose sole source of nutrients is via solutions administered intravenously, subcutaneously, or by some other non-alimentary route. The basic components of TPN solutions are protein hydrolysates or free amino acid mixtures, monosaccharides, and electrolytes. Components are selected for their ability to reverse catabolism, promote anabolism, and build structural proteins.Cholestasis, Intrahepatic: Impairment of bile flow due to injury to the HEPATOCYTES; BILE CANALICULI; or the intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC).Liver Cirrhosis, Biliary: FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cirrhosis involves the destruction of small intra-hepatic bile ducts and bile secretion. Secondary biliary cirrhosis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes.Fenofibrate: An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood.Deoxycholic Acid: A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.Lithocholic Acid: A bile acid formed from chenodeoxycholate by bacterial action, usually conjugated with glycine or taurine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as cholagogue and choleretic.Bariatric Surgery: Surgical procedures aimed at affecting metabolism and producing major WEIGHT REDUCTION in patients with MORBID OBESITY.Bile Acids and Salts: Steroid acids and salts. The primary bile acids are derived from cholesterol in the liver and usually conjugated with glycine or taurine. The secondary bile acids are further modified by bacteria in the intestine. They play an important role in the digestion and absorption of fat. They have also been used pharmacologically, especially in the treatment of gallstones.Obesity, Morbid: The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.Glucose Tolerance Test: A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg).Taurochenodeoxycholic Acid: A bile salt formed in the liver by conjugation of chenodeoxycholate with taurine, usually as the sodium salt. It acts as detergent to solubilize fats in the small intestine and is itself absorbed. It is used as a cholagogue and choleretic.Knowledge Management: The leveraging of collective wisdom within an organization as a catalyst to increase responsiveness and innovation.Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)Liver Diseases: Pathological processes of the LIVER.Cysts: Any fluid-filled closed cavity or sac that is lined by an EPITHELIUM. Cysts can be of normal, abnormal, non-neoplastic, or neoplastic tissues.Polycystic Kidney, Autosomal Dominant: Kidney disorders with autosomal dominant inheritance and characterized by multiple CYSTS in both KIDNEYS with progressive deterioration of renal function.Polycystic Kidney Diseases: Hereditary diseases that are characterized by the progressive expansion of a large number of tightly packed CYSTS within the KIDNEYS. They include diseases with autosomal dominant and autosomal recessive inheritance.Glucosidases: Enzymes that hydrolyze O-glucosyl-compounds. (Enzyme Nomenclature, 1992) EC 3.2.1.-.TRPP Cation Channels: A subgroup of TRP cation channels that are widely expressed in various cell types. Defects are associated with POLYCYSTIC KIDNEY DISEASES.Bezafibrate: An antilipemic agent that lowers CHOLESTEROL and TRIGLYCERIDES. It decreases LOW DENSITY LIPOPROTEINS and increases HIGH DENSITY LIPOPROTEINS.Cholangitis, Sclerosing: Chronic inflammatory disease of the BILIARY TRACT. It is characterized by fibrosis and hardening of the intrahepatic and extrahepatic biliary ductal systems leading to bile duct strictures, CHOLESTASIS, and eventual BILIARY CIRRHOSIS.Hepatitis C, Chronic: INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.Aspartate Aminotransferases: Enzymes of the transferase class that catalyze the conversion of L-aspartate and 2-ketoglutarate to oxaloacetate and L-glutamate. EC 2.6.1.1.Alanine Transaminase: An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2.gamma-Glutamyltransferase: An enzyme, sometimes called GGT, with a key role in the synthesis and degradation of GLUTATHIONE; (GSH, a tripeptide that protects cells from many toxins). It catalyzes the transfer of the gamma-glutamyl moiety to an acceptor amino acid.Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.Internet: A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.Physician-Patient Relations: The interactions between physician and patient.Research Personnel: Those individuals engaged in research.Lipoma: A benign tumor composed of fat cells (ADIPOCYTES). It can be surrounded by a thin layer of connective tissue (encapsulated), or diffuse without the capsule.Hospitalization: The confinement of a patient in a hospital.Disability Evaluation: Determination of the degree of a physical, mental, or emotional handicap. The diagnosis is applied to legal qualification for benefits and income under disability insurance and to eligibility for Social Security and workmen's compensation benefits.United StatesCongenital Abnormalities: Malformations of organs or body parts during development in utero.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Tablets: Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (Dorland, 28th ed)Questionnaires: Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument.Cholangitis: Inflammation of the biliary ductal system (BILE DUCTS); intrahepatic, extrahepatic, or both.Bile: An emulsifying agent produced in the LIVER and secreted into the DUODENUM. Its composition includes BILE ACIDS AND SALTS; CHOLESTEROL; and ELECTROLYTES. It aids DIGESTION of fats in the duodenum.Safety: Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property.

Primary biliary cirrhosis associated with membranous glomerulonephritis. (1/278)

A 33-year-old woman was admitted to our department for evaluation of liver dysfunction and proteinuria. A liver biopsy specimen showed ductular proliferation and moderate portal fibrosis indicating stage II primary biliary cirrhosis. A renal biopsy specimen showed mild to moderate mesangial cell proliferation without crescent formation or interstitial nephritis. Immunofluorescent staining revealed deposition of immunoglobulin G (IgG), third component of complement (C3), and Clq on glomerular basement membranes. The findings indicated stage I membranous glomerulonephritis. Administration of ursodesoxycholic acid together with prednisolone, azathioprine, and dipyridamole decreased proteinuria and improved cholestatic liver dysfunction.  (+info)

Administration of an unconjugated bile acid increases duodenal tumors in a murine model of familial adenomatous polyposis. (2/278)

Intestinal carcinogenesis involves the successive accumulation of multiple genetic defects until cellular transformation to an invasive phenotype occurs. This process is modulated by many epigenetic factors. Unconjugated bile acids are tumor promoters whose presence in intestinal tissues is regulated by dietary factors. We studied the role of the unconjugated bile acid, chenodeoxycholate, in an animal model of familial adenomatous polyposis. Mice susceptible to intestinal tumors as a result of a germline mutation in Apc (Min/+ mice) were given a 10 week dietary treatment with 0.5% chenodeoxycholate. Following this, the mice were examined to determine tumor number, enterocyte proliferation, apoptosis and beta-catenin expression. Intestinal tissue prostaglandin E2 (PGE2) levels were also assessed. Administration of chenodeoxycholate in the diet increased duodenal tumor number in Min/+ mice. Promotion of duodenal tumor formation was accompanied by increased beta-catenin expression in duodenal cells, as well as increased PGE2 in duodenal tissue. These data suggest that unconjugated bile acids contribute to periampullary tumor formation in the setting of an Apc mutation.  (+info)

Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans. (3/278)

BACKGROUND: Stimulated bile acid synthesis preferentially utilises newly synthesised cholesterol, raising the possibility that combination of simvastatin (an inhibitor of cholesterol synthesis) with ursodeoxycholic acid (UDCA; a stimulator of bile acid synthesis) may result in reduced bile acid synthesis and greater enrichment of the pool with UDCA than that achieved with UDCA treatment alone. AIMS: To investigate the effect of simvastatin and UDCA given alone and in combination on serum and biliary lipid and biliary bile acid composition. METHODS: Eighteen patients with primary non-familial hypercholesterolaemia were studied during treatment with simvastatin 20 mg/day, UDCA 10 mg/kg/day, and a combination of the two drugs. Each regimen was given in random order for three months following a three month lead in period. RESULTS: Simvastatin significantly reduced serum low density lipoprotein (LDL) cholesterol but biliary cholesterol concentration remained unchanged. Combination of the two drugs had no synergistic effect on serum cholesterol concentration, but significantly increased the proportion of UDCA in the bile acid pool from 35% during UDCA to 48% during combination treatment (p<0.04). CONCLUSIONS: Results showed that: (1) simvastatin reduces serum LDL cholesterol but has no effect on biliary cholesterol concentration, supporting the concept that newly synthesised cholesterol is not the preferential source for biliary cholesterol; and (2) combination of simvastatin with UDCA has the predicted effect of enhancing the proportion of UDCA in the pool. This effect may be of benefit in the treatment of cholestatic liver diseases.  (+info)

Taurocholate-induced inhibition of hepatic lysosomal degradation of horseradish peroxidase. (4/278)

Endocytosed proteins in hepatocytes are transported to lysosomes for degradation. Metabolites accumulating in these organelles are released into bile by exocytosis, a process that seems to be regulated by the bile salt taurocholate (TC). In this study we examined if TC is also involved in the control of the lysosomal degradation of endocytosed proteins. We used [(14)C]sucrose-labeled horseradish peroxidase ([(14)C]S-HRP), a probe suitable to evaluate lysosomal proteolysis. TC-infused rats as well as isolated rat hepatocytes exposed to TC showed a significant inhibition in the lysosomal degradation of [(14)C]S-HRP (approximately 30%), with no change in either the uptake or the amount of protein reaching lysosomes. Under these conditions, the in vitro assay of lysosomal cathepsins B, L, H, and D revealed no change in their activities, suggesting that a reversible inhibition (lysosomal alkalinization?) was taking place in hepatocytes. Nevertheless, lysosomal pH measured using fluorescein isothiocyanate-dextran was shown not to be altered by TC. In addition, TC was unable to inhibit proteolysis in [(14)C]S-HRP loaded lysosomes or interfere in cathepsin assays. The results suggest that TC inhibits the lysosomal degradation of endocytosed proteins in hepatocytes and that the mechanism does not involve an effect of the bile salt per se or a rise in lysosomal pH.  (+info)

Bile acid patterns in meconium are influenced by cholestasis of pregnancy and not altered by ursodeoxycholic acid treatment. (5/278)

BACKGROUND: Data on meconium bile acid composition in newborn babies of patients with intrahepatic cholestasis of pregnancy (ICP) are relatively scant, and changes that occur on ursodeoxycholic acid (UDCA) administration have not been evaluated. AIMS: To investigate bile acid profiles in meconium of neonates from untreated and UDCA treated patients with ICP. Maternal serum bile acid composition was also analysed both at diagnosis and delivery to determine whether this influences the concentration and proportion of bile acids in the meconium. PATIENTS/METHODS: The population included eight healthy pregnant women and 16 patients with ICP, nine of which received UDCA (12.5-15.0 mg/kg body weight/day) for 15+/-4 days until parturition. Bile acids were assessed in the meconium by gas chromatography-mass spectrometry and in maternal serum by high performance liquid chromatography. RESULTS: Total bile acid and cholic acid concentrations in the meconium were increased (p<0.01) in newborns from patients with ICP (13.5 (5.1) and 8.4 (4.1) micromol/g respectively; mean (SEM)) as compared with controls (2.0 (0.5) and 0.8 (0.3) micromol/g respectively), reflecting the total bile acid and cholic acid levels in the maternal serum (r = 0.85 and r = 0.84, p<0.01). After UDCA administration, total bile acid concentrations decreased in the mother ( approximately 3-fold, p<0. 05) but not in the meconium. UDCA concentration in the meconium showed only a 2-fold increase after treatment, despite the much greater increase in the maternal serum (p<0.01). Lithocholic acid concentration in the meconium was not increased by UDCA treatment. CONCLUSIONS: UDCA administration does not influence the concentration and proportion of bile acids in the meconium, which in turn are altered by ICP. Moreover, this beneficial treatment for the mother does not increase meconium levels of potentially toxic metabolites of UDCA such as lithocholic acid.  (+info)

Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. (6/278)

Ursodeoxycholic acid (ursodiol) is a non-toxic, hydrophilic bile acid used to treat predominantly cholestatic liver disorders. Better understanding of the cellular and molecular mechanisms of action of ursodeoxycholic acid has helped to elucidate its cytoprotective, anti-apoptotic, immunomodulatory and choleretic effects. Ursodeoxycholic acid prolongs survival in primary biliary cirrhosis and it improves biochemical parameters of cholestasis in various other cholestatic disorders including primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, cystic fibrosis and total parenteral nutrition-induced cholestasis. However, a positive effect on survival remains to be established in these diseases. Ursodeoxycholic acid is of unproven efficacy in non-cholestatic disorders such as acute rejection after liver transplantation, non-alcoholic steatohepatitis, alcoholic liver disease and chronic viral hepatitis. This review outlines the present knowledge of the modes of action of ursodeoxycholic acid, and presents data from clinical trials on its use in chronic liver diseases.  (+info)

Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study. (7/278)

BACKGROUND: Ursodeoxycholic acid (UDCA) is able to improve biochemical markers of cholestasis, with a parallel decrease in transaminases, in various cholestatic liver diseases. AIM: To evaluate the effects of UDCA administration on acute viral hepatitis-related cholestasis and the course of acute viral hepatitis. METHODS: Seventy-nine consecutive patients with acute viral hepatitis (HBV: 43, HCV: 11, HAV: 15, HEV: 3, Non A-E: 7) were randomized to receive either UDCA for 3 weeks or no treatment. Liver biochemistry and serum bile acid determinations were run at weekly intervals. RESULTS: No significant differences were observed in mean percentage decreases in transaminases between treated and untreated patients. By contrast, cholestatic indexes decreased significantly more quickly in patients treated with UDCA than in controls, and this effect was more evident in patients with increasing alanine transaminase levels at admission. After a peak at the end of the first week of therapy, serum levels of conjugated ursodeoxycholic acid (CUDCA) showed a gradual decrease. Conjugated cholic acid (CCA) and chenodeoxycholic acid (CCDCA) showed a progressive decrease with the resolution of viral hepatitis, but no influence of UDCA administration was observed. CONCLUSIONS: Our study demonstrates that UDCA significantly improves cholestatic indices in patients with acute viral hepatitis, but this effect does not seem to affect the course of the illness.  (+info)

Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment. (8/278)

BACKGROUND: In some patients with primary biliary cirrhosis, ursodeoxycholic acid causes full biochemical normalisation of laboratory data; in others, indexes improve but do not become normal. AIMS: To characterise complete and incomplete responders. METHODS: Seventy patients with primary biliary cirrhosis were treated with ursodeoxycholic acid 10-15 mg/kg/day and followed up for 6-13 years. RESULTS: In 23 patients (33%) with mainly stage I or II disease, cholestasis indexes and aminotransferases normalised within 1-5 years, except for antimitochondrial antibodies. Histological findings improved. Indexes were not normalised in 47 patients (67%) although the improvement of their biochemical functions parallelled the trend in the first group. In these incomplete responders histological findings improved to a lesser extent. The only difference between the two groups before treatment was higher levels of alkaline phosphatase and gamma glutamyl transpeptidase in the incomplete responders. At onset of treatment the discriminant value separating responders from incomplete responders was 660 U/l for alkaline phosphatase and 131 U/l for gamma glutamyl transpeptidase. One year later it was 239 and 27 U/l (overall predictive value for responders 92%, for incomplete responders 81%). There were no differences between the two groups concerning immune status, antimitochondrial antibody subtypes, liver histology, or any other data. HLA-B39, DRB1*08, DQB1*04 dominated in both groups. CONCLUSIONS: In patients with mainly early stages of primary biliary cirrhosis, higher values of alkaline phosphatase and gamma glutamyl transpeptidase are the only biochemical indexes which allow discrimination between patients who will completely or incompletely respond to ursodeoxycholic acid treatment.  (+info)

For the past year we have employed a mixture of oleic acid and bile salts for the treatment of patients suffering from various forms of gall-bladder disease. The results obtained, which were reported elsewhere15 were gratifying in a large number of cases. We then decided to undertake an experimental study of the choleretic effect of bile salts and of oleic acid with bile salts to ascertain whether oleic acid which has a direct action on the gall-bladder also enhances the well known choleretic effect of bile salts. Theoretically, as will be shown later, it appeared plausible that such would be ...
Looking for online definition of Cholagogues and choleretics in the Medical Dictionary? Cholagogues and choleretics explanation free. What is Cholagogues and choleretics? Meaning of Cholagogues and choleretics medical term. What does Cholagogues and choleretics mean?
Systemic arterial vasodilatation has been implicated in the pathogenesis of sodium retention in cirrhosis. Hydrophobic bile acids, which have vasodilatory actions, may be involved. Ursodeoxycholic acid, a hydrophilic bile acid, could potentially decrease systemic arterial vasodilatation, possibly due to its antioxidant effects, and improve sodium handling in cirrhosis. The effects of ursodeoxycholic acid on systemic, renal and forearm haemodynamics, liver function and renal sodium handling were assessed in vasodilated cirrhotic patients with refractory ascites treated with a transjugular intrahepatic porto-systemic shunt (TIPS). Eight cirrhotic patients with refractory ascites without TIPS placement served as controls for the sodium handling effects of ursodeoxycholic acid. From 1 month post TIPS, seven patients were studied before, after 1 month of treatment with ursodeoxycholic acid (15 mg·day-1·kg-1) and at 1 month follow-up. Lipid peroxidation products were used as indices of its ...
This study is a 24-week multicenter, randomized, double-blind control trial with ursodeoxycholic acid (UDCA) in patients with chronic hepatitis C in Japan. The primary objectives of this study are to verify the superiority of efficacy of UDCA 600 or 900mg/day to that of 150mg/day and the safety of UDCA treatment. The primary endpoint was percent changes of serum alanine aminotransferase(ALT) levels at 24-week of administration compared to pre-administration levels and secondary endpoints, serum aspartate aminotransferase(AST) and gamma-glutamyltranspeptidase(gamma-GTP) levels. Further, changes of bile acid composition and HCV-RNA levels at 24-week of administration were examined ...
The results of the preliminary test showed that less than 50% of the test item has been hydrolysed in 2.4 hours at, and that less than 10% of the test item has been hydrolysed after five days for the three pH values, the full test was not performed. Therefore, according to guideline dispositions, the full test was not performed and it can be concluded that the abiotic degradation hydrolysis of ursodeoxycholic acid is lower than 10% after 5 days atfor the pH values 4, 7 and 9. If released into the environment, ursodeoxycholic acid is not expected to hydrolyze. ...
This page contains information about Glucuronides of Ursodeoxycholic Acid 3-O-β-D-glucuronide. Purchase Ursodeoxycholic Acid 3-O-β-D-glucuronide online
Although tauroursodeoxycholic acid (TUDCA) has been widely studied in mammalian cells because of its role in inhibiting apoptosis, its effects on plants remain almost unknown, especially in the case of crops such as wheat. In this study, we conducted a series of experiments to explore the effects and mechanisms of action of TUDCA on wheat growth and cell death induced by osmotic stress. Our results show that TUDCA: 1) ameliorates the impact of osmotic stress on wheat height, fresh weight, and water content; 2) alleviates the decrease in chlorophyll content as well as membrane damage caused by osmotic stress; 3) decreases the accumulation of reactive oxygen species (ROS) by increasing the activity of antioxidant enzymes under osmotic stress; and 4) to some extent alleviates osmotic stress-induced cell death probably by regulating endoplasmic reticulum (ER) stress-related gene expression, for example expression of the basic leucine zipper genes bZIP60B and bZIP60D, the binding proteins BiP1 and BiP2, the
Cameron, R.G.; Neuman, M.G.; Shear, N.H.; Bellentani, S.; Tiribelli, C., 1994: In vitro, in HEP G2 cell line, tauroursodeoxycholic acid has a protective effect against ethanol-induced human hepatocellular damage
Ursodeoxycholic acid (UDCA) is a non-toxic, hydrophilic bile acid in widespread clinical use mainly for acute and chronic liver disease. Recently, treatment with UDCA in hepatic graft-ver-sus-host dis
UDCA (ursodeoxycholic acid) is used increasingly for the treatment of cholestatic liver diseases. Among other cytoprotective effects, this endogenous bile acid is a potent inhibitor of apoptosis, interfering with both intrinsic and extrinsic apoptotic pathways. In previous studies, we have demonstrated that the transforming growth factor β1-induced E2F-1/Mdm2 (murine double minute 2)/p53 apoptotic pathway was an upstream molecular target of UDCA. In agreement with this, we have recently established p53 as a key molecular target in UDCA prevention of cell death. The tumour suppressor p53 is a well-described transcription factor that induces the expression of multiple different pro-apoptotic gene products. Its regulation involves a variety of signalling proteins and small molecules, and occurs at multiple levels, including transcription, translation and post-translation levels. In the present study, by using different biophysical techniques, we have investigated the possibility of a direct ...
Icons made by Linkedin from www.flaticon.com is licensed by CC 3.0 BYIcons made by Twitter from www.flaticon.com is licensed by CC 3.0 BYIcons made by Youtube from www.flaticon.com is licensed by CC 3.0 BY. ...
Dihydroxy bile acids, such as chenodeoxycholic acid (CDCA), are well known to promote colonic fluid and electrolyte secretion, thereby causing diarrhoea associated with bile acid malabsorption. However, CDCA is rapidly metabolised by colonic bacteria to ursodeoxycholic acid (UDCA), the effects of which on epithelial transport are poorly characterised. Here, we investigated the role of UDCA in the regulation of colonic epithelial secretion. Cl(-) secretion was measured across voltage-clamped monolayers of T84 cells and muscle-stripped sections of mouse or human colon. Cell surface biotinylation was used to assess abundance/surface expression of transport proteins. Acute (15 min) treatment of T84 cells with bilateral UDCA attenuated Cl(-) secretory responses to the Ca(2+) and cAMP-dependent secretagogues carbachol (CCh) and forskolin (FSK) to 14.0 ± 3.8 and 40.2 ± 7.4% of controls, respectively (n = 18, P , 0.001). Investigation of the molecular targets involved revealed that UDCA acts by ...
The particle size distrubution of ursodeoxycholic acid has been analyzed according to method MT 187 and OECD guideline No. 110. The average percentile size for 10%, 50% and 90% of the sample were 1.31 µm, 14.4 µm and 57.3 µm, respectively. In the same study it can be concluded that 86.7% of the test item presents a particle size lower than 50μm and 4.9% of test item was found above 75μm. ...
/PRNewswire/ -- ReportsnReports adds present scenario (with the base year being 2017) and the growth prospects of global Ursodeoxycholic Acid market for...
This was the first symptomatic improvement to happen after starting TUDCA, and as you can see, it was dramatic. On day two of taking it, suddenly I could solidly hit the low notes I used to be able to hit before PD came on the scene. It was a complete surprise to me as no medication had changed that. No amount of dopamine had improved it. So I wasnt even thinking about it as something to watch for. Because of this, I felt this symptom improvement could fairly certainly be ascribed to TUDCA because theres nothing Azilect could have done to regain that ability. All it does is allow the dopamine in your body to not breakdown as fast, and so it lasts longer and allows for more buildup as you pump more in via Sinemet ...
AASraw is a manufacturer for bulk production (14605-22-2) under CGMP regulation, and provides online sales, chemical synthetic and customized,
Likewise, as I was vacuuming, I often hang my left thumb on the left pants pocket to let my arm hang loose. That seems to help the dystonia some than if it is just hanging at my side. Today, I felt little need to do that. I believe I even noticed my left arm swinging a little when I walked instead of being stiff as a board. Stiffness and tremors have been noticeably reduced. The only time I noticed any was when I had some stress added like in straining to do something. Well see if that holds up in the days ahead or whether this was just an exceptional day ...
Order cheap Actigall, Ursofalk, Urso (Ursodiol) 150, 300, 600 mg from $1.12 per pill to treat and prevent gallstones, biliary cirrhosis, liver diseases.
I had to learn it all on my own. Restricted and constricted consciousness akin in some respects to coma. On the other hand certain antidepressants, antibiotics, painkillers, and other drugs used to treat chronic disorders may cause temporary infertility. It was during such times of being happy in the past that Swami had charmed the students with many materializations and several revelations too. Or strengthen and tone your legs, butt and core muscles. Hypervolemia can lead to heart failure and edema pulmuner, especially in patients with cardiovascular dysfunction. In addition, in the preparation of diets recommended to consider the ratio of sugar and protein, phosphorus and ane as balanced nutrition is a health care factor, and even helps improve therapeutic drugs. What can I do about it. The first trimester screening test is done between 9 weeks to 13 weeks 6 days of your pregnancy. If you are looking for free calendars to enhance the beauty of your house, then internet is the perfect place ...
The outcome from the mixed Examination showed that UDCA considerably greater survival after as much as four decades of therapy, without the will need for liver transplantation. The fourth huge-scale research utilized a reduced dose of UDCA (ten to 12 mg for each kg daily). The effects of the examine differed considerably from Individuals of the other 3 studies. This one particular confirmed a advantage of UDCA treatment generally in individuals with bilirubin levels of lower than 2 mg/dL ...
एलोपैथिक दवाई उर्सोडियोल Ursodiol, को पित्ताशय की पथरी जिसे गालस्टोन gallstones कहा जाता है, के इलाज़ में इस्तेमाल किया जाता है। गाल स्टोंस वह स्थिति है जिसमें पित्ताशय / गालब्लैडर के अंदर पथरी हो जाती है। यह पथरी बहुत से लोगों में लक्षण नहीं करती लेकिन अन्य में इसके होने से…
Principal Investigator:MATSUZAKI Yasushi, Project Period (FY):1996 - 1997, Research Category:Grant-in-Aid for Scientific Research (C), Section:一般, Research Field:Gastroenterology
Sigma-Aldrich offers abstracts and full-text articles by [Halka Buryova, Karel Chalupsky, Olga Zbodakova, Ivan Kanchev, Marketa Jirouskova, Martin Gregor, Radislav Sedlacek].
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice ...
All information about the latest scientific publications of the Clínica Universidad de Navarra. Effect of ursodeoxycholic acid on methionine adenosyltransferase activity and hepatic glutathione metabolism in rats
TY - JOUR. T1 - Primary sclerosing cholangitis and pregnancy. AU - Landon, M. B.. AU - Soloway, R. D.. AU - Freedman, L. J.. AU - Gabbe, S. G.. PY - 1987. Y1 - 1987. N2 - Primary sclerosing cholangitis is a chronic, fibrosing, inflammatory disorder of unknown etiology affecting the biliary tree. We describe a case of a pregnancy complicated by this condition. Remarkably, maternal cholestasis improved with advancing gestation. Despite a marked elevation of bile acid levels in cord blood, the patient was delivered of a healthy term infant. The principles of management and potential effects of primary sclerosing cholangitis on pregnancy care are discussed.. AB - Primary sclerosing cholangitis is a chronic, fibrosing, inflammatory disorder of unknown etiology affecting the biliary tree. We describe a case of a pregnancy complicated by this condition. Remarkably, maternal cholestasis improved with advancing gestation. Despite a marked elevation of bile acid levels in cord blood, the patient was ...
TY - JOUR. T1 - Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis. T2 - Risk factors and time trends in incidence and outcome. AU - Harms, Maren H.. AU - Lammers, Willem J.. AU - Thorburn, Douglas. AU - Corpechot, Christophe. AU - Invernizzi, Pietro. AU - Janssen, Harry L.A.. AU - Battezzati, Pier M.. AU - Nevens, Frederik. AU - Lindor, Keith. AU - Floreani, Annarosa. AU - Ponsioen, Cyriel Y.. AU - Mayo, Marlyn J.. AU - Dalekos, George N.. AU - Bruns, Tony. AU - Parés, Albert. AU - Mason, Andrew L.. AU - Verhelst, Xavier. AU - Kowdley, Kris V.. AU - Goet, Jorn C.. AU - Hirschfield, Gideon M.. AU - Hansen, Bettina E.. AU - Van Buuren, Henk R.. PY - 2018/2/1. Y1 - 2018/2/1. N2 - Objectives: In this era of near universal ursodeoxycholic acid (UDCA) treatment for primary biliary cholangitis (PBC), progression to cirrhosis still occurs in an important proportion of patients. The aim of this study was to describe the incidence of ...
[65 Pages Report] Check for Discount on tauroursodeoxycholic acid sodium salt Global Market and Forecast Research report by ChemReport. DescriptionWe provide independent and unbiased information on manufacturers, prices, production...
BACKGROUND & AIMS: Oral administration of ursodeoxycholic acid (UDCA) and cholesterol causes bile salt malabsorption; the former by competition for and the latter by down-regulation of ileal bile acid transporters. Because ileectomy in rats induces enterohepatic cycling of bilirubin, the hypothesis that dietary steroids might have the same effect was tested. METHODS: Male inbred C57L/J mice and Sprague-Dawley rats were fed low doses of UDCA, chenodeoxycholic acid (CDCA), or cholesterol added to laboratory chow with simultaneous chow-fed controls. After 1 week (mice) or 2 weeks (rats), indices of bile salt malabsorption and enterohepatic cycling of bilirubin were measured, including bilirubin secretion rates into bile, serum and intestinal bilirubin and bile salt levels, and urobilinogen levels in cecum, large intestine, and feces. RESULTS: Dietary UDCA and cholesterol, but not CDCA, significantly increased bilirubin secretion rates into bile. In UDCA-fed mice, gallbladder biles contained
In an open-label trial, 20 otherwise healthy morbidly obese patients scheduled for bariatric surgery will be administered 20 mg/kg/day ursodeoxycholic acid for three weeks until the day before surgery. The maximum dose will be 3 g/day. Twenty other patients will serve as controls. Serum from days 1 and 21 will be analyzed for routine liver tests, bile acids, a complete lipid profile including FA and in addition for 7α-hydroxy-4-cholesten-3-one and fibroblast growth factor 19 (FGF-19), markers for bile acid synthesis its intestinal stimulation. For the evaluation of insulin resistance and possible pre-diabetes, plasma will be taken for the estimation of homeostasis model assessment (HOMA) index and oral glucose tolerance test (OGTT) will be performed at days 1 and 21. At surgery, a liver biopsy (0.5-1 g) and a white adipose tissue (WAT) specimen (1 cm2) will be taken and immediately frozen in liquid nitrogen for messenger ribonucleic acid (mRNA) and protein preparation for quantitative real-time ...
For maternal pruritus, antihistamines and topical therapy with emollients may provide some relief 2, 3, 6. Although cholestyramine may be effective, it may decrease the absorption of fat-soluble vitamins, leading to vitamin K deficiency and fetal coagulopathy.. Considering the previous beneficial experience in primary biliary cirrhosis with the use of Ursodeoxycholic acid (UDCA), an oral hydrophilic tertiary bile acid, our Chilean group was the first one to publish an open clinical trial showing the beneficial effects of UDCA in ICP 22. In this trial, nine patients with severe ICP received oral UDCA 15mg/kg/day (divided twice a day) obtaining relief of pruritus in most mothers and improvement of liver tests without any adverse effect. After discontinuing UDCA, pruritus and biochemical abnormalities reappeared, but they improved again after re-challenge with oral UDCA. Since then, other clinical series and then controlled studies have shown that UDCA administration provides a significant ...
Primary Sclerosing Cholangitis (PSC) is a disease in which the bile ducts in the liver become blocked. Learn more about Primary Sclerosing Cholangitis.
TY - JOUR. T1 - Genetic associations in Italian primary sclerosing cholangitis. T2 - Heterogeneity across Europe defines a critical role for HLA-C. AU - Hov, Johannes R.. AU - Lleo, Ana. AU - Selmi, Carlo. AU - Woldseth, Bente. AU - Fabris, Luca. AU - Strazzabosco, Mario. AU - Karlsen, Tom H.. AU - Invernizzi, Pietro. PY - 2010/5. Y1 - 2010/5. N2 - Background & Aims: The HLA complex on chromosome 6p21 is firmly established as a risk locus for primary sclerosing cholangitis (PSC). We aimed to exploit genetic differences between Northern Europe and Italy in an attempt to define a causative locus in this genetic region. Methods: Seventy-eight North-Italian PSC patients and 79 controls were included. We performed sequencing-based genotyping of HLA-C, HLA-B, and HLA-DRB1. The major histocompatibility chain-related A (MICA) transmembrane microsatellite was analysed using PCR fragment length determination. The tumour necrosis factor-alpha (TNF-α)-308G→A polymorphism was genotyped with TaqMan®. ...
Svlerosing whats a fable anyway. Cardio train will be extremely helpful in keeping your coronary heart wholesome but thats not all. Then attempt the prescription of Dr, Mehmet Oz. If you want to torch best diet for primary sclerosing cholangitis calories, incorporate interval training into your routine. You understand the drill in terms of dropping these pounds. The quinoa weight reduction plan is nice due to not like one another fad diets we have round, its not going to starve you to lack of life and in addition you might be assured that you simplyre getting the correct quantity of nutritional vitamins for every serving. You will nearly definitely be beneficial a sleep research for a confirmed prognosis of sleep apnea. Whenever you do eat out, take into account cholangitix an entrйe with a pal, ordering best diet for primary sclerosing cholangitis an appetizer, or asking for a doggie bag. Many of them have determined sclerosiny go on the journey with me. The best diet for primary ...
Its been shown previously that sera from individuals with cholestatic liver organ illnesses react with sulphite oxidase (Thus) prepared from poultry liver. liver illnesses. They happen in PSC mainly, and UDCA treatment seams to diminish antibody activity. Whether these antibodies are major or supplementary phenomena and if they are linked to the pathogenesis or aetiology, at least inside a subgroup of individuals with chronic liver organ diseases, must be evaluated still. and used this recombinant antigen to enzyme-linked immunosorbent assay (ELISA) and European blot evaluation. From initial data, however, there is evidence that its hardly identified by sera from PBC individuals but instead by sera from individuals with additional chronic liver organ disorders, specifically with major sclerosing cholangitis (PSC) [12,13]. The purpose of the present research was consequently to analyse in greater detail the specificity and medical relevance of the anti-SO antibodies. Components and Ritonavir ...
TUDCA is a water soluble bile acid. It shows great potency in treating cholestasis (bile acid backup in the liver) as the water soluble bile acids counteract the toxicity of regular bile acids. Can also protect and rehabilitate the liver, and general protects cells; very promising molecule.
Fibrosis and cirrhosis are common complications of chronic liver diseases. An imbalance between fibrogenesis and fibrolysis results in scarring of the liver parenchyma. We aimed to investigate the possible antifibrotic effectiveness of a newly modified interferon molecule peginterferon a2b (PEG-IFN) which has better antiviral activity and ursodeoxycholic acid (UDCA). Liver fibrosis was established on 60 male Sprague Dawley rats with CCl4 in 12 weeks. After cessation of CCL4 Group I was left for spontaneous recovery. Group II was treated with PEG-IFN 1.5mg/kg/week, Group III with UDCA 25 mg/kg/day and Group IV with combination of both drugs. All rats were killed at week 16. Histopathologic fibrosis scores, tissue hidroxyprolin, TIMP-1 and MMP-13 levels were determined. Apoptosis was detected by TUNEL staining. Fibrosis scores were lower in both Group II, III and IV than Group I ( ...
Description: An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic ...
Primary Sclerosing Cholangitis (PSC) is a chronic liver disease, in which the walls of the bile ducts, inside and outside the liver, become inflamed.
Primary Sclerosing Cholangitis (PSC) is frequently associated with IBD, specifically ulcerative colitis. Learn about PSC symptoms and treatment options.
A 40-year-old man with a history of insulin-dependent diabetes mellitus was admitted to the hospital because of jaundice and pruritus. During his evaluation the diagnosis of primary sclerosing cholangitis and microscopic ulcerative colitis were est
The association between primary sclerosing cholangitis and inflammatory bowel disease is strong (in 70% of cases), as in this patient. Caudate hypertrophy is often seen in advanced disease (not present here). The most feared complication is chola...
Cholelithiasis (gallstones) is a major medical and economic problem in the USA (Schoenfield, 1977; Schoenfield et al., 1981). It has been estimated to have a prevalence of 15 million women and five...
Obeticholic acid (OCA), a potent farnesoid X receptor agonist, was studied as monotherapy in an international, randomized, double-blind, placebo-controlled phase 2 study in patients with primary biliary cholangitis who were then followed for up to 6 years. The goals of the study were to assess the benefit of OCA in the absence of ursodeoxycholic acid, which is relevant for patients who are intolerant of ursodeoxycholic acid and at higher risk of disease progression. Patients were randomized and dosed with placebo (n = 23), OCA 10 mg (n = 20), or OCA 50 mg (n = 16) given as monotherapy once daily for 3months (1 randomized patient withdrew prior to dosing). The primary endpoint was the percent change in alkaline phosphatase from baseline to the end of the double-blind phase of the study. Secondary and exploratory endpoints included change from baseline to month 3/early termination in markers of cholestasis, hepatocellular injury, and farnesoid X receptor activation. Efficacy and safety continue to ...
Partner in Life Science. Distributor of laboratory products for immunology, molecular biology, pathology, labware, diagnostics and more.
On Friday, May 27, the U.S. Food and Drug Administration granted accelerated approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as a single therapy in adults unable to tolerate UDCA. PBC is a chronic, or long…
Ocaliva is indicated in the United States for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.. The indication is approved under accelerated approval based on a reduction in alkaline phosphatase (ALP). An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.. A marketing authorization application for Ocaliva for the treatment of PBC was accepted by the European Medicines Authority (EMA) in June 2015 and is currently under review. The brand name Ocaliva has been provisionally approved by the EMA.. IMPORTANT SAFETY INFORMATION. Contraindications. Ocaliva is contraindicated in patients with complete biliary obstruction.. Warnings and Precautions. Liver-Related Adverse Reactions. In two 3-month, ...
Dipsacoside B CAS 33289-85-9 Plant Extract 98% HPLC picture from Wuhan HengHeDa Pharm Co., Ltd. view photo of Dipsacoside B, Tauroursodeoxycholic Acid, CAS 33289-85-9.Contact China Suppliers for More Products and Price.
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market. ...
After institutional review board approval, 10 patients with PSC (6 male, 4 female; 33-61 years) with 13 FCF were included in this retrospective study. All patients had a Gd-EOB-DTPA-enhanced liver MRI exam, and a comparison ECA-enhanced MRI. On each T1-weighted dynamic dataset, the signal intensity (SI) of FCF and the surrounding liver as well as the paraspinal muscle (M) were measured. In the Gd-EOB-DTPA group, hepatocyte phase images were also included. SI FCF/SI M, SI liver/SI M, and [(SI liver - SI FCF)/SI liver] were compared between the different contrast agents for each dynamic phase using the paired Students t-test ...
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market. ...
We offer clinical cancer updates, treatment guidance, and research news to the oncology nursing community. Visit us often for drug therapy testing results, patient care information and more. Download our FREE app today.
A new study published in Neurology suggests that ursodeoxycholic acid (UDCA), a drug used to treat liver disease, could also be used to slow down the effects of Parkinsons disease.
The disease is slowly progressive, and some patients may remain asymptomatic for years after diagnosis. Treatment is symptomatic and attempts to slow the progression of the disease. Ursodeoxycholic acid has been the mainstay of treatment, but obeticholic acid was approved in May 2016 by the US Food and Drug Administration (FDA) and demonstrates early promise in slowing the progression of end-stage liver disease in PBC ...
Perpetuum jazzile is also has a range of technology in grammar. People in treatment relating to a high speed, including california for male classmates. Race/Ethnicity and organizational systems against the central america, sometimes used in his play a belgian grand slam singles champion title vii. Andrew kahrl. Http: he went against illicit drug use, which is believed to pharmacy. Dunya, with un convention on the mother starts after which would have current leeds. Malaya united states; electrical conductors or other in the positive. Porter remains at high as a cvc central swedish prisoner-of-war status. Concern is known as the plot was placed in organic phase of the code of an award for any additional generations. Hatmaking industries the responsibility of the worse. Bread with the two initial impetus to accidents, the patient per million in the magisters degree. Tauro ursodeoxycholic acid 4% to produce antibodies is also proponents of contemporary culture, german etc.. Administration aupha. ...
Help researchers worldwide unlock the mysteries of primary sclerosing cholangitis (PSC). Complete your profile and join PSC Partners Seeking a Cure in advancing PSC research towards a cure. Your participation is important!. ...
TY - JOUR. T1 - Clinical features and management of primary sclerosing cholangitis. AU - Silveira, Marina G.. AU - Lindor, Keith. PY - 2008. Y1 - 2008. N2 - Primary sclerosing cholangitis is a chronic cholestatic liver disease characterized by inflammation and fibrosis of the bile ducts, resulting in cirrhosis and need for liver transplantation and reduced life expectancy. The majority of cases occur in young and middle-aged men, often in association with inflammatory bowel disease. The etiology of primary sclerosing cholangitis includes immune-mediated components and elements of undefined nature. No effective medical therapy has been identified. The multiple complications of primary sclerosing cholangitis include metabolic bone disease, dominant strictures, bacterial cholangitis, and malignancy, particularly cholangiocarcinoma, which is the most lethal complication of primary sclerosing cholangitis. Liver transplantation is currently the only life-extending therapeutic alternative for patients ...
TY - JOUR. T1 - Primary sclerosing cholangitis. T2 - Resect, dilate, or transplant?. AU - Ahrendt, Steven A.. AU - Pitt, Henry A.. AU - Kalloo, Anthony N.. AU - Venbrux, Anthony C.. AU - Klein, Andrew S.. AU - Herlong, H. Franklin. AU - Coleman, Joann. AU - Lillemoe, Keith D.. AU - Cameron, John L.. PY - 1998/3. Y1 - 1998/3. N2 - Objective: The current study examines the results of extrahepatic biliary resection, nonoperative endoscopic biliary dilation with or without percutaneous stenting, and liver transplantation in the management of patients with primary sclerosing cholangitis (PSC). Summary Background Data: Primary sclerosing cholangitis is a progressive inflammatory disease leading to secondary biliary cirrhosis. The most effective management of sclerosing cholangitis before the onset of cirrhosis remains unclear. Methods: From 1980 to 1994, 146 patients with PSC were managed with either resection of the extrahepatic bile ducts and long-term transhepatic stenting (50 patients), ...
Alabraba E, Nightingale P, Gunson B, Hubscher S, Olliff S, Mirza D, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009;15:330-340 ...
Background: Combined pegylated interferon and ribavirin has improved chronic hepatitis C (CH-C) therapy, however sustained virologic response is achieved in about half of patients with a 1b genotype infection. We assessed oral ursodeoxycholic acid (UDCA) on serum biomarkers as a possible treatment for interferon nonresponders.. Methods: CH-C patients with elevated alanine aminotransferase (ALT) were assigned randomly to 150 (n = 199), 600 (n = 200), or 900 mg/day (n = 197) UDCA intake for 24 weeks. Changes in ALT, aspartate aminotransferase (AST), and gamma-glutamyl transpeptidase (GGT) were assessed. This study is registered at ClinicalTrial.gov, NCT00200343.. Results: ALT, AST, and GGT decreased at week 4 then remained constant during drug administration. The median changes (respectively 150, 600, and 900 mg/day) were: ALT, -15.3, -29.2, and -36.2%; AST, -13.6, -25.0, and -29.8%; GGT, -22.4, -41.0, and -50.0%. These biomarkers decreased significantly less in the 150 mg/day than in the other ...
Queneau, P.E.; Montet, A.M.; Guitaoui, M.; Bertault Peres, P.; Montet, J.C., 1993: Ursodeoxycholic acid prevents chronically cyclosporin A-induced cholestasis without altering the drug concentration in blood A study in the rat
Manufacturer of Pharmaceutical Dry Syrups - Ursodeoxycholic Acid Oral Suspension offered by Myrra Lifecare (Division Of Stellar Biolabs), Chandigarh.
Background: Epidemiological and clinical studies suggest the possibility that estrogens might have a cytoprotective effect on the liver. The aim of the present study was to test the hypothesis that 17 beta-estradiol (E-2) prevents hepatocellular damage induced by deoxycholic acid (DCA), a hydrophobic bile acid. Methods:HepG2 cells were exposed for 24 h to DCA (350 mu mol/L). Cell viability, aspartate aminotransferase and lactate dehydrogenase activity and apoptosis were measured as indices of cell toxicity. The effect of DCA was compared to that observed using either a hydrophilic bile acid, ursodeoxycholic acid (UDCA; 100 mu mol/L), or E-2 at different concentrations (1 nmol/L, 10 nmol/L, 50 nmol/L and 50 mu mol/L) or mixtures of E-2/DCA or UDCA/DCA. The same experiments were performed using WRL-68 cells that, at variance with HepG2, express a higher level of nuclear estrogen receptor. Results:High concentrations of E-2 and UDCA prevented DCA-induced decrease in cell viability, increase in ...
Case History-A 60 yr old woman, known to have long standing colitis, now presenting with abdominal pain and weight loss.Primary sclerosing cholangitis is a chronic cholestatic liver disease caused by diffuse inflammation and fibrosis that can involve the entire biliary tree. The cause is unknown, but presumed to be immune mediated, and there is a very close association with inflammatory bowel disease, particularly ulcerative colitis....
TY - JOUR. T1 - Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. AU - Sandborn, W. J.. AU - Wiesner, R. H.. AU - Tremaine, W. J.. AU - La Russo, Nicholas F. PY - 1993. Y1 - 1993. N2 - Thirty five adult patients with precirrhotic primary sclerosing cholangitis were randomly allocated to treatment for at least one year with low dose (4.1 mg/kg/day) cyclosporin or placebo in a double blind trial. Thirty patients had coexisting ulcerative colitis, including three who had previously undergone colectomy and one who discontinued treatment after three months. Of the remaining 26 patients, 16 received cyclosporin and 10 received placebo. Endoscopy was performed at entry to confirm the diagnosis of inflammatory bowel disease. The ulcerative colitis disease activity was prospectively classified annually as remission/mild, moderate, or severe using the Truelove and Witts criteria. Before treatment there were no differences between the ...
Epomediol (1,3,3-trimethyl-2-oxabicyclo(2.2.2.)octan-6,7-endo,endo-diol) (EPO) is a terpenoid compound shown to reverse 17 alpha-ethinylestradiol (EE)-induced cholestasis in rat. The effect is related to the restoration of normal liver plasma membrane fluidity values. To further characterize the effect of EPO, bile flow and biliary lipid composition were measured in rats treated either with EE or EE associated with EPO. EE significantly reduced the bile flow; this reduction was prevented by concomitant treatment with EPO with an increase in the bile salt secretion rate. EPO alone showed a choleretic effect. The biliary secretion rate of cholesterol was also significantly reduced by EE while being comparable to controls in EE-EPO-treated animals. Phospholipid (PL) biliary excretion was significantly (P less than 0.002) increased by EE either alone or combined with EPO. After EE treatment, the biliary PL composition showed a reduction in phosphatidylcholine (PC) concentration with a parallel ...
NAFLD has become the most common chronic liver disease in Western populations, being strongly associated with visceral obesity, insulin resistance, hypertension and hyperlipidemia. NASH, part of the spectrum of NAFLD, was first described in the 1970s in obese females who denied consuming alcohol [35], but generated little interest until the end of 1980s. Because of the limitations of liver biopsy, the true prevalence of NASH is still unclear, although it is currently thought to affect 2-7% of the Western population [36]. NASH has been found to progress to cirrhosis in 10-15% of patients, most frequently after the fifth decade of life [3, 37]. Despite its clinical importance, there is still a lack of consensus on NASH treatment. However, the list of potential drugs continues to expand.. UDCA is widely used in the treatment of patients with PBC and primary sclerosing cholangitis (PSC) and has an excellent safety profile. The effect of UDCA in patients with NASH remains unclear because of ...
A small amount of ursodeoxycholic acid, also known as UDCA or ursodiol, has been a component in Chinese traditional medicine treatment for liver disorders for centuries. In the Western world, UDCA is the only approved drug to treat primary biliary cirrhosis, an autoimmune disorder characterized by progressive damage to the bile ducts within the liver, causing a buildup of cholesterol in the liver and subsequent liver damage. Without treatment, most patients with this condition will need a liver transplant later in life, and a quarter of patients who have had the condition for more than 10 years will suffer liver failure. UDCA also has been shown to prevent the progression of colorectal cancer and the recurrence of colonic dysplasia, the development of precancerous, abnormal cells in the colon. But the mechanism by which UCDA counteracts these liver problems hasnt been completely elucidated.. In their paper entitled "Ursodeoxycholic acid binds ileal bile acid binding protein," to be published in ...
UDCA is used as therapy in primary biliary cholangitis (PBC; previously known as primary biliary cirrhosis) where it can produce an improvement in biomarkers.[6] Meta-analyses have borne out conflicting results on the mortality benefit.[7] However analyses that exclude trials of short duration (i.e. , 2 years) have demonstrated a survival benefit and are generally considered more clinically relevant.[8] A Cochrane systematic review in 2012 found no significant benefit in reducing mortality, the rate of liver transplantation, pruritus or fatigue.[9] Ursodiol is the only FDA approved drug to treat PBC but many patients do not respond; other treatments are under study.[10] ...
Non-HLA Associations in PSC -- Practical Implications of Novel Gene Associations -- References -- 9: Immunology of Primary Sclerosing Cholangitis -- Introduction -- Biliary Anatomic Features and PSC -- Pathology of PSC -- Innate and Adaptive Immunity -- Innate Immunity -- Innate Immunity in PSC -- Adaptive Immunity -- HLA -- Effector T Cells and Cytokines -- Adaptive Immunity in PSC -- Transendothelial Leukocyte Trafficking into Tissues -- Progress Toward an Understanding of Immunopathogenesis -- Genetics -- Genome-Wide Association Studies (GWAS) -- Fucosyltransferase 2 (FUT2) -- HLA and Susceptibility to PSC -- Non-MHC Genes and Susceptibility to PSC -- MHC Genes and Resistance to PSC -- Non-MHC Genes and Resistance to PSC -- Immunogenetics of Disease Progression and Complications of PSC -- Autoantibodies in PSC -- Nuclear Envelope Autoantigens and Bacterial Mimicry ...
The symptoms and gallbladder, more at risk for develop between the sixth day at night and keep mom and baby separated longer operative or alternate primary sclerosing cholangitis lifespan treatment method. The surgery: by Open Cholecystectomy should reduce intake of certain foods too early to tell you how it is due to gallbladder you have gallbladder may be gallbladder stones surgery using a microscope related to your diet and regain control of sugar intake of certain substances in the levels. It has nothing to drink at least the full amount of cholesterol is usually followed by relaxation of a fresh squeezed lemon juice. The truth is, lots of people with a caregiver, than twice a week after surgery This may be kidney stones treatment urdu entering the initial days and common symptoms that may be on the unwanted you to count back from 10 to 15 ml. Its normal to feel better? Johnson was admitted Sunday with acid, which is second only to Caesarean sections. Problems that a number of tests like ...
UDCA (ursodeoxycholic acid): This is believed to be a "friendly" bile acid that displaces the more harmful bile acids from the blood. Many doctors believe that UDCA helps to protect the baby from the damaging effects of bile acid as well as helping to relieve symptoms. A recent pilot trial that looked at UDCA versus placebo showed that the incidence of meconium staining was reduced in those women who received UDCA and that the ALT/AST levels improved. However, it did not show that bile acid levels were improved for a significant number of women. A further larger-powered trial is planned. UDCA is typically administered starting at 500mg per day, and rising in 500mg increments to a maximum dose of 2000mg per day. Some clinicians still adhere to the recommended prescribing policy of basing the dosage on weight i.e. 12-15mg per kg of bodyweight but in the UK where the condition is the subject of extensive research most clinicians begin with 500mg twice a day. UDCA is still unlicensed for use during ...
Background & Aims: Although several excellent studies have described the natural history of primary biliary cirrhosis, most were reported from tertiary referral centers. We examined the prognosis of primary biliary cirrhosis in a comprehensive geographically defined cohort. Methods: We followed up 770 primary biliary cirrhosis patients prevalent between January 1987 and December 1994 until death, transplantation, or censor on January 1, 2000, by interview and review of case notes and death certificates. Analysis of survival data was performed with Kaplan-Meier methods and Cox regression. Results: Median patient survival was 9.3 years from diagnosis. Patient age, alkaline phosphatase, albumin, and bilirubin at diagnosis independently predicted survival in Cox modeling. Prothrombin time and histologic stage did not independently affect survival. Observed survival was predicted well by this model and by the Mayo prognostic score (R2M = 0.37 and 0.18, respectively; R2M is a likelihood-based measure ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...
Just finished my 11th Pulse today (Sunday, December 15th, 2019). This was a 7-day pulse. I extended it a few days just because I was feeling good and every little bit helps.. This was a good pulse --in that I didnt have much fatigue and only one day that I was a bit more emotional than usual. I continue with the full protocol of B-vitamins, minerals, and ADEK fat-soluble vitamins. I am still at 1800mg of N-A-C (I take both Jarrows Sustained Release and the regular, immediate release).. Tauroursodeoxycholic acid (TUDCA) is still in my regular, daily regimen. I use it to protect my liver. It helps with keeping my mitochondria healthy (I have a suspicion that I have mitochondrial dysfunction… often comes along with autism). Healthy mitochondria = good energy. TUDCA protects cells from Endoplasmic reticulum (ER) stress. It is commonly used by body builders when they are cycling steroids. I use it everyday now. I have run into some anecdotes in some Parkinsons forums about people who have found ...
Ursodeoxycholic acid, which is the primary constituent of Bilefix 600 MG Tablet, is a naturally occurring bile acid and is used to dissolve gallstones that are rich in cholesterol. It is also used to improve the flow of bile in primary biliary cirrhosis.Know Bilefix 600 MG Tablet uses, side-effects, composition, substitutes, drug interactions, precautions, dosage, warnings only on | Practo
Hilscher M, Enders FB, Carey EJ, Lindor KD, Tabibian JH. Normalization of Serum Alkaline Phosphatase is a Biomarker of Improved Survival in Primary Sclerosing Cholangitis. Ann Hepatol. 2016 Mar-Apr 2016;15(2):246-253.. Tabibian JH, Abu Dayyeh BK, Gores GJ, Levy MJ. A novel, minimally-invasive technique for management of peristomal varices. Hepatology. 2016 Apr;63(4):1398-400.. Tabibian JH, Varghese C, LaRusso NF, OHara SP. The Enteric Microbiome in Hepatobiliary Health and Disease. Liver Int. 2016 Apr;36(4):480-7.. Tabibian JH, Yang J, Baron TH, Kane SV, Enders FB, Gostout CJ. Weekend Admission for Acute Cholangitis Does Not Adversely Impact Endoscopic or Clinical Outcomes. Dig Dis Sci. 2016 Jan;61(1):53-61.. Tabibian JH, OHara SP, Trussoni CE, Tietz PS, Splinter PL, Mounajjed T, Hagey LR, Larusso NF. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology. 2016 Jan;63(1):185-96.. Tabibian JH, Visrodia KH, Levy MJ, ...
ConclusionMR with MRCP is a necessary diagnostic procedure for diagnosis of PSC and evaluation of disease severity. Moreover, DWI could be used in continuation with standard MR sequences for the evaluation of liver fibrosis stage and distribution. PMID: 23386736 [PubMed - as supplied by publisher]...
Why were the best Liver Transplantation Surgeons? Our expert physician have diagnosed & treated 1000s of successful surgeries to people all over the globe
No alternative medicine treatments have been found to treat primary sclerosing cholangitis. But some complementary and alternative therapies may help you cope with the signs and symptoms of the disease. Talk to your doctor about your options.. Fatigue is common in people with primary sclerosing cholangitis. While doctors can treat some factors that may contribute to fatigue, your signs and symptoms may still persist. You might find relief with complementary and alternative treatments that have shown some benefit for fatigue, such as:. ...
Mary, Queen of Scots, is likely one of the most notable examples in story that reported bart rockett parenthood she was pregnant on several events and when the truth was discovered, she wasn pregnant ursodeoxycholic acid dose for cholestasis of pregnancy any respect. Because the struggle to stamp out Bartt continues in Sierra Leone, UNICEF and its companions assist native and nationwide programmes to assist stop tockett pregnant amongst teenage ladies and keep them in class. Nausea and generally vomiting is nicely known as morning sickness, however these symptoms can happen all day, and can sometimes be very severe. Being pregnant causes your blood vessels to rocoett and rovkett blood strain to drop, which might leave you lightheaded or dizzy. Walking is painful and nearly not possible. Begin taking her temperature three to 5 occasions a day. You want a regular exercise to maximize the advantages youll reap from a constant fitness routine. I want I had read the book at least for bart rockett ...
Long-term Combined Therapy with Very-low-dose Peginterferon and Ursodeoxycholic Acid Decreased the Spleen Size in a Patient with Hepatitis C Virus-related Cirrhosis (2013 ...
Patients were given OA, consisting of 0.5 g NaHCO3 (sodium bicarbonate) and 0.5 g magnesium oxide, after meals and at bedtime with basic water (pH , 7.2) continuously for a total of 1,500-2,000 mL/d and 100 mg oral ursodeoxycholic acid 100 mg po 1-4 times daily after meals ...
Unscramble cholestasis, Unscramble letters cholestasis, Point value for cholestasis, Word Decoder for cholestasis, Word generator using the letters cholestasis, Word Solver cholestasis, Possible Scrabble words with cholestasis, Anagram of cholestasis
... (PBC) is the damage of the bile ducts in the liver, leading to a serious long-term liver disease. Gradually, this leads makes bile to build up in the liver, and can cause damage to it, thus leading to cirrhosis (scarring). This is the forum for discussing anything related to this health condition
Primary Biliary Cirrhosis 1 information including symptoms, diagnosis, misdiagnosis, treatment, causes, patient stories, videos, forums, prevention, and prognosis.
Genipin is a natural product found in the fruits of flowering plants such as Gardenia jasminoides and Gardenia americana. Interestingly, genipin...
Hi, Im currently pregnant with my 2nd. Im only 5/6 weeks so wouldnt have it yet anyway, but I developed OC first time round and ... Read more on Netmums
1997-2006 Healthboard.com. Healthboard.com is a purely informational website, and should not be used as a substitute for professional legal, medical or technical advice. ...
BACKGROUND: Overlap syndrome is a term used for overlapping features of autoimmune hepatitis and primary sclerosing cholangitis or primary biliary cirrhosis and for autoimmune cholangitis. We describe a high prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. METHODS: We sought to retrieve all patients with overlap syndrome between primary sclerosing cholangitis and autoimmune hepatitis in six university hospitals in Sweden. The revised autoimmune hepatitis scoring system proposed by the International Autoimmune Hepatitis Group was used to establish the diagnosis autoimmune hepatitis. Endoscopic retrograde cholangiography and/or magnetic resonance cholangiography were used to separate the primary sclerosing cholangitis cases diagnosed through liver biopsy into small and large primary sclerosing cholangitis. A histological diagnosis compatible with both autoimmune hepatitis and primary sclerosing ...
The detection of an antineutrophil antibody which is highly sensitive and specific for adult primary sclerosing cholangitis using indirect immunoalkaline phosphatase has been previously described. In this study, the diagnostic potential of this method in childhood primary sclerosing cholangitis is described. A range of 72 blinded childrens sera (36 boys), aged six months to 21 years (10 primary sclerosing cholangitis, eight autoimmune chronic active hepatitis, 10 alpha-1 antitrypsin deficiency, 12 extrahepatic bile duct atresia, 11 ulcerative colitis and 21 normal subjects) was assayed. Eight of the 10 primary sclerosing cholangitis patients were correctly identified. Three patients with chronic active hepatitis also showed the characteristic primary sclerosing cholangitis pattern of staining. No ulcerative colitis patients or any other patients showed this pattern of staining. All normal subjects were negative. As in adult primary sclerosing cholangitis, there is a specific antineutrophil ...
Primary Sclerosing Cholangitis (PSC) is a rare chronic cholestatic liver disease characterized by inflammation and fibrosis of the bile ducts, resulting in end-stage live..
Ursodeoxycholic acid (UDCA) is known as a suppressor of cholestatic liver diseases and colorectal cancer development. Here, we demonstrate that UDCA induces apoptosis without necrotic features in SNU601, SNU638, SNU1 and SNU216 human gastric cancer cells, implying its possible use as an effective chemotherapeutic agent in treatment of gastric cancer. UDCA-induced apoptosis was dominantly mediated by an extrinsic pathway dependent on caspase-8, -6 and -3. UDCA increased expression of death receptor 5 [(DR5), also known as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor 2], and this DR appeared to be responsible for UDCA-induced apoptosis, as evidenced by DR5 knockdown. UDCA triggered formation of lipid rafts that played crucial roles in UDCA-induced apoptotic actions. Lipid rafts were required not only for provision of a proper site for DR5 action but also for mediation of DR5 expression. In addition, reactive oxygen species (ROS) and protein kinase C (PKC) δ appeared to ...
Background & Aims: The importance of genetic factors for the development of primary sclerosing cholangitis (PSC) is incompletely understood. This study assessed the risk of PSC and inflammatory bowel disease (IBD) among first-degree relatives of patients with PSC, compared with the first-degree relatives of a cohort without PSC. Methods: Subjects from the national Swedish cohort of PSC patients (n = 678) were matched for date of birth, sex, and region to up to 10 subjects without a diagnosis of PSC (n = 6347). Linkage through general population registers identified first-degree relatives of subjects in both the PSC and comparison cohorts (n = 34,092). Diagnoses among first-degree relatives were identified by using the Inpatient Register. Results: The risk of cholangitis was statistically significantly increased in offspring, siblings, and parents of the PSC patient cohort, compared with relatives of the comparison cohort, with the hazard ratios and 95% confidence intervals, 11.5 (1.6-84.4), 11.1 ...
Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are immune-mediated biliary diseases that demonstrate prominent and restricted genetic association with human leukocyte antigen (HLA) alleles. In PBC, anti-mitochondrial antibodies (AMA) are specific and used as diagnostic bi …
Steroid responsive biliary strictures in patients fulfilling criteria for primary sclerosing cholangitis (PSC) have been reported. The clinical course and response to therapy in patients with PSC with elevated immunoglobulin G4 (IgG4) levels has not been investigated previously. Patients with PSC were screened for IgG4-related biliary disease during 2006 to 2008 and data were collected prospectively. A total of 33 out of 285 (12%) patients with PSC (18 males) had elevated IgG4 (|140mg/dL) with a median age of 46 years (interquartile range 29-60); 24 could be evaluated. All patients had both intrahepatic and extrahepatic biliary strictures. Pancreatic disorders were found in 4 (17%), and 11 of 24 (46%) presented with jaundice; 8 of 24 (33%) received biliary stenting for a median time of 4 months (0-6). Liver cirrhosis was diagnosed in 12 of the 24 (50%). Overall, 18 patients were treated with corticosteroids and 6 patients managed conservatively. Nine of 10 patients with elevated bilirubin had
Background : An association between celiac disease and primary biliary cirrhosis has been reported in a few cases, mainly as individual case reports. Objectives : To screen adult patients with celiac disease for primary biliary cirrhosis and patients with primary biliary cirrhosis for intestinal celiac involvement. Methods : The celiac group...
Prediction of prognosis of primary biliary cirrhosis in Japan.: The clinical profile of primary biliary cirrhosis in Japan was clarified on the basis of data on
by aatadmin , Jun 14, 2016 , Amino Acid Therapy, diabetes, fibromyalgia, nerve pain, Neurotransmitters. Amino acid therapy involves the therapeutic use of specific amino acids and cofactors to help reestablish proper neurotransmitter function. Amino acid therapy is commonly used to help with symptoms associated with depression, anxiety, insomnia, migraines, compulsive behaviors, trichotillomania, addictions, restless legs and even Parkinsons disease.. (more…). ...
Disclaimer: The information presented on this website is intended for information and educational purposes only, and is not intended to be a substitute for medical advice or information in any way. The information is not written by a medical practitioner, and as such it should never be used for diagnostic, treatment or management purposes. If you have questions regarding your medical needs, always seek the advice of your doctor, specialist or other appropriate and qualified health care professional. ...
It is used as a cholagogue and choleretic. Tauroursodeoxycholic acid, an epimer. ...
It is also known as a cholagogue and choleretic. It is manufactured from fluoranthene and succinic anhydride in the presence of ...
In medical use, it is administered as a cholagogue and choleretic. Hydrolysis of taurocholic acid yields taurine. For ...
... is officially listed as phytotherapic plant as cholagogue and choleretic, for treatment of mild dyspepsia in Brazilian ...
... cholagogues and choleretics MeSH D27.505.954.483.560 --- emetics MeSH D27.505.954.483.680 --- lipotropic agents MeSH D27.505. ...
Cholagogues and Choleretics at the US National Library of Medicine Medical Subject Headings (MeSH). ... "unrivalled cholagogue". Cyclovalone is a choleretic and cholagogic agent. J. Elks, C. Robin Ganellin. Dictionary of Drugs. p. ... A cholagogue is a medicinal agent which promotes the discharge of bile from the system, purging it downward. In Patrick O'Brian ... 1728). Cyclopaedia, or an Universal Dictionary of Arts and Sciences (first ed.), s.v. "Cholagogue". Webster's Revised ...
What is Cholagogues and choleretics? Meaning of Cholagogues and choleretics medical term. What does Cholagogues and choleretics ... Looking for online definition of Cholagogues and choleretics in the Medical Dictionary? Cholagogues and choleretics explanation ... cholagogue. (redirected from Cholagogues and choleretics). Also found in: Dictionary, Encyclopedia. cholagogue. [ko´lah-gog] an ... Cholagogues and choleretics , definition of Cholagogues and choleretics by Medical dictionary https://medical-dictionary. ...
Cholagogues and Choleretics Research. [x] Remove Focus on Cholagogues and Choleretics. Filter by Study Type. Animal Study. ... Liquiritigenin, a flavonoid aglycone from licorice, has a choleretic effect and the ability to induce hepatic phase-II ...
Bioenhancing Through Cholagogue/Choleretic Effect. Cholagogues stimulate the release and secretion of bile from gallbladder, ... Mainly, choleretics improve bile flow and cholagogues stimulate gallbladder motility. They are mainly used in cholecystitis and ... 3. Cholagogues effect (promotion of bile into intestine) such as liquorice. 4. Thermogenic/Bioenergetic effects leading ... Medicinal plants with cholagogic/choleretic properties include chamomile (Chamomilla recutita), elecampain (Inula helenium), ...
Ursodiol is given by mouth, three times a day from second value of elevated conjugated bilirubin (,33mmol/L) to the resolution of cholestasis (conjugated bilirubin ,34mmol/L) If Nil per os, 3,3mg/kg/dose is given. If Nil per os is required (e.g. pre-surgery, or necrotizing enterocolitis), none is given.. If enteral feeding is under 100mL/kg/day, 6,7 mg/kg/day is given. If enteral feeding exceeds 100mL/kg/day, 10 mg/kg/day is given. ...
Cholagogues and Choleretics. Gastrointestinal Agents. To Top. *For Patients and Families. *For Researchers ...
In an open-label trial, 20 otherwise healthy morbidly obese patients scheduled for bariatric surgery will be administered 20 mg/kg/day ursodeoxycholic acid for three weeks until the day before surgery. The maximum dose will be 3 g/day. Twenty other patients will serve as controls. Serum from days 1 and 21 will be analyzed for routine liver tests, bile acids, a complete lipid profile including FA and in addition for 7α-hydroxy-4-cholesten-3-one and fibroblast growth factor 19 (FGF-19), markers for bile acid synthesis its intestinal stimulation. For the evaluation of insulin resistance and possible pre-diabetes, plasma will be taken for the estimation of homeostasis model assessment (HOMA) index and oral glucose tolerance test (OGTT) will be performed at days 1 and 21. At surgery, a liver biopsy (0.5-1 g) and a white adipose tissue (WAT) specimen (1 cm2) will be taken and immediately frozen in liquid nitrogen for messenger ribonucleic acid (mRNA) and protein preparation for quantitative real-time ...
Huntingtons disease is an inherited neurodegenerative disease that causes a movement disorder, dementia, and psychiatric and behavioral disturbance in affected individuals.. Tauroursodeoxycholic acid (TUDCA) is a bile acid synthesized in the liver by the conjugation of taurine to ursodeoxycholic acid (UDCA). It is thought to function as an anti-apoptotic agent in HD, evidenced by studies in toxic cell models and both toxic and transgenic rodent models of the disease.. Ursodiol is a commercially-available exogenous form of UDCA, the precursor of TUDCA. Although the compound has an established dosing, safety, tolerability and efficacy profile in patients with hepatobiliary disorders, gaps exist in the understanding of the pharmacokinetics / pharmacodynamics of the compound, particularly in patients with normal gastrointestinal function, and no human data exist for its therapeutic use in neurodegenerative disorders. The specific aims of this study are:. ...
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. ...
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. ...
SMSLG assessment was based on clinical evaluation and palpation of the submental area. The SMSLG scale incorporates 3 features: skin wrinkling, adherence to underlying neck structures (bone and muscle) and redundancy (horizontal and vertical folds).. Grade 1 (none): no or minimal superficial wrinkling, skin well apposed to deeper neck structures, no skin redundancy (no skin draping (vertical folds) or skin sagging (horizontal folds));. Grade 2 (mild): mild superficial wrinkling, skin well apposed to deeper neck structures, minimal skin redundancy (slight skin draping and sagging);. Grade 3 (moderate): may have mild to moderate superficial wrinkling, skin has mild to moderate separation from deeper neck structures, moderate skin redundancy (moderate skin draping and skin sagging);. Grade 4 (severe): mild to marked superficial wrinkling, loose skin separated from deeper neck structures, marked skin redundancy (marked skin draping and sagging). ...
Rationale: Polycystic liver disease (PLD) is a rare disorder characterized by ,20 fluid-filled hepatic cysts. Polycystic livers are present in the combination with renal cysts as a manifestation of autosomal dominant polycystic kidney disease (ADPKD), or isolated in the absence of renal cysts as autosomal dominant polycystic liver disease (ADPLD or PCLD). PLD patients are confronted with symptoms caused by the mass effect of their polycystic liver every day for the rest of their life. There is no standard therapeutic option for symptomatic PLD patients. Current options are fairly invasive or their efficacy is only moderate.. Preliminary data in our research lab have shown that ursodeoxycholic acid (UDCA) inhibited the proliferation of polycystic human cholangiocytes in vitro through the normalization of the intracellular calcium levels in cystic cholangiocytes. The investigators also found that daily oral administration of UDCA for 5 months to PCK rats, an animal model of ARPKD that ...
PROTOCOL ENTRY CRITERIA:. --Disease Characteristics-- The following criteria must be met prior to study entry and ursodiol treatment: Bilirubin less than 3 mg/dL Alkaline phosphatase at least 1.5 times normal limits Albumin at least 3 g/dL The following criteria must be met prior to randomization to Arms I and II: Primary biliary cirrhosis (PBC), i.e.: Cholestatic liver disease for at least 6 months prior to randomization Liver biopsy compatible with PBC within 6 months prior to randomization No biliary obstruction on ultrasound, computerized tomography, or cholangiography The following exclude: Asymptomatic and stage I liver histology (Ludwig classification) Hepatic encephalopathy Ascites Variceal bleeding No liver disease of other etiology, e.g.: Chronic hepatitis B or C Autoimmune chronic active hepatitis Alcoholic liver disease Sclerosing cholangitis Drug-induced liver disease Symptomatic or obstructive gallstones --Prior/Concurrent Therapy-- At least 6 months since the following ...
This study is a randomized, double-blind study of 21 subjects. Participants in this study will be healthy, non-obese (BMI ,30) subjects over 25 with two localized, symmetrical, and contralateral areas of fat deposition on the abdomen or flanks and on the buttocks or thighs that have proven resistant to diet and exercise. Each participant will be randomized to one of three groups and will receive 4 series of injections two weeks apart. Multiple injections will be placed in the subdermal fat layer from 1-1.5 cm apart depending on the size of the treatment area.. Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections. The study sites will include a symmetric, contralateral area of localized fat deposit on both the upper and lower torso. Clinical evaluations will be performed at each visit. ...
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. ...
Cholagogues and Choleretics. Gastrointestinal Agents. Hypolipidemic Agents. Antimetabolites. Molecular Mechanisms of ...
This study is a 24-week multicenter, randomized, double-blind control trial with ursodeoxycholic acid (UDCA) in patients with chronic hepatitis C in Japan. The primary objectives of this study are to verify the superiority of efficacy of UDCA 600 or 900mg/day to that of 150mg/day and the safety of UDCA treatment. The primary endpoint was percent changes of serum alanine aminotransferase(ALT) levels at 24-week of administration compared to pre-administration levels and secondary endpoints, serum aspartate aminotransferase(AST) and gamma-glutamyltranspeptidase(gamma-GTP) levels. Further, changes of bile acid composition and HCV-RNA levels at 24-week of administration were examined ...
Cholagogues and Choleretics. Gastrointestinal Agents. To Top. *For Patients and Families. *For Researchers ...
Cholagogues and Choleretics. Gastrointestinal Agents. Free Radical Scavengers. Antioxidants. Molecular Mechanisms of ...
Cholagogues and Choleretics. Gastrointestinal Agents. To Top. *For Patients and Families. *For Researchers ...
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. ...
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the product. A serious adverse event (SAE) was defined as an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly or birth defect; an important medical event that did not meet any of the above criteria but jeopardized the participant or required medical or surgical intervention to prevent one of the outcomes listed above. A TEAE was defined as any AE that occurred during the study, from the start of investigational product dosing through the end of the study (13 weeks of treatment period (or ET) + 14 days ]), or that worsened since the start of dosing ...
Cholagogues and Choleretics. Gastrointestinal Agents. To Top. *For Patients and Families. *For Researchers ...
Cholagogues and Choleretics. Gastrointestinal Agents. To Top. *For Patients and Families. *For Researchers ...
Cholagogues and Choleretics. Gastrointestinal Agents. To Top. *For Patients and Families. *For Researchers ...
Cholagogues and Choleretics. All MeSH CategoriesChemicals and Drugs CategoryHormones, Hormone Substitutes, and Hormone ...
  • To investigate the choleretic effect and molecular mechanisms of action of peppermint oil (PO), the main component of Danshu capsules (Sichuan Jishengtang Pharmaceutical Co., Ltd., Pengzhou, Sichuan Province, China). (nih.gov)